FDA's Peptide Review Signals New Era for Cosmetics–Device Boundaries

The US Food and Drug Administration is convening in July to review several key peptides used across the beauty industry. On the surface, this looks like a cosmetics story. But for regulatory affairs teams working at the convergence of cosmetics, medical devices, and software-enabled diagnostics, it's a regulatory boundary redefinition that will ripple across multiple product categories—and it's happening while AI-driven formulation and skin diagnostics are already blurring those lines further.

At stake: whether peptides—molecules that have become ubiquitous in anti-aging, barrier repair, and skin health products—retain their cosmetic classification or shift toward therapeutic claims that trigger device or drug pathways. The implications extend far beyond ingredient suppliers. For any organisation developing skin diagnostic tools, wearable skin sensors, AI-powered personalised skincare platforms, or connected devices that recommend formulations, this review represents a fundamental shift in how regulators will assess claims, evidence, and the boundary between 'cosmetic effect' and 'medical purpose.'

Why Peptides Matter Beyond Cosmetics Formulation

Peptides occupy a uniquely contested space. Unlike traditional cosmetic ingredients that sit comfortably on one side of the regulatory line, peptides make structure–function claims—collagen synthesis, barrier repair, inflammation modulation—that sound a lot like therapeutic endpoints. That's always been a grey area. But as AI-driven formulation tools (highlighted at the recent Society of Cosmetic Scientists Annual Conference) enable real-time personalisation based on skin barrier diagnostics, and as wearable devices start measuring transepidermal water loss, sebum levels, and inflammatory markers to recommend specific peptide formulations, the regulatory stakes escalate fast.

If the FDA decides that certain peptides—or specific claims associated with them—cross into therapeutic territory, manufacturers will face a choice: reformulate, reclassify, or build an evidence package that satisfies device or drug pathways. For startups developing AI-powered skin diagnostic platforms or connected beauty devices, this creates a dual compliance challenge. Your software algorithm might remain a General Wellness product or Class I device under current guidance—but if it's recommending formulations that now require substantiation as medical devices, your entire regulatory strategy shifts overnight.

This isn't hypothetical. We've already seen similar dynamics play out with UV monitoring wearables, acne analysis apps, and dermatology-focused digital therapeutics. Each began as 'wellness' or 'cosmetic adjacent' and encountered regulatory escalation once claims touched clinical endpoints. The peptide review represents the FDA making that boundary explicit—and doing so at a moment when AI is accelerating product convergence across categories.

AI, Skin Diagnostics, and the New Compliance Landscape

The Society of Cosmetic Scientists conference underscored how rapidly AI is reshaping product development. Speakers from Coty, Elemis, and Unilever discussed AI-driven formulation, skin barrier health research, and ethical test methods that replace traditional in vivo studies with predictive models. This is powerful innovation—but it introduces regulatory complexity that many teams aren't yet equipped to navigate.

When your AI model predicts skin barrier dysfunction and recommends a peptide-rich formulation to 'repair' it, have you just made a therapeutic claim? When your wearable device measures sebum oxidation and suggests a specific peptide to modulate inflammation, are you now a combination product? If the FDA reclassifies key peptides, the answers change—and your compliance roadmap with them.

For regulatory teams, this convergence demands a more sophisticated approach than traditional cosmetics or device pathways allow in isolation. You need to understand how AI-driven adaptability and post-market design loops inform continuous evidence generation, especially when your product's recommendations evolve based on user data. You need to anticipate how algorithmic transparency requirements—already tightening for SaMD—will intersect with substantiation obligations for cosmetics claims. And you need to build regulatory strategies that can flex across jurisdictions, because what the FDA decides in July will influence MHRA, Health Canada, and other regulators who are watching closely.

What This Means for Your Team

If you're developing products that sit anywhere near the cosmetics–device boundary, the FDA's peptide review is your signal to act now—not after the ruling. Here's what practical preparation looks like.

First, audit your product claims and ingredient substantiation. If your device, app, or platform recommends formulations containing peptides, map every claim back to the evidence that supports it. Don't assume cosmetic precedent will hold. If your marketing language includes terms like 'repair,' 'restore,' 'treat,' or 'improve skin health,' you're already in grey territory. Work with your regulatory and marketing teams to align on language that reflects your intended classification—and ensure your clinical or technical evidence can defend it.

Second, if you're using AI to personalise recommendations, document your algorithm's decision logic now. The FDA's evolving expectations around AI explainability mean that 'black box' models are no longer defensible, especially when outputs influence therapeutic decisions. You need to be able to explain why your algorithm recommended a specific peptide formulation, what clinical endpoints it's optimising for, and how you validated that recommendation against real-world outcomes. That's not just good science—it's becoming a regulatory requirement.

Third, consider your post-market surveillance strategy. If peptides move toward device classification, you'll need continuous monitoring of safety signals, user-reported outcomes, and formulation effectiveness. That's a heavier lift than traditional cosmetics vigilance, and it requires infrastructure most beauty-tech startups don't yet have. Build those capabilities now, before you're mandated to retrofit them.

Finally, engage with regulatory counsel early—especially if you're planning to expand beyond the US market. The MHRA's recent approval of Retifanlimab for Merkel cell skin cancer (a targeted oncology therapy) underscores that UK and EU regulators are actively defining therapeutic boundaries in adjacent skin health categories. Your US strategy won't automatically translate. You need jurisdiction-specific advice that accounts for divergence in how cosmetics, devices, and biologics are classified across markets.

The Broader Regulatory Shift: Convergence and Continuous Evidence

The peptide review is part of a larger pattern: regulators are tightening oversight wherever product categories converge and where digital tools enable new claims. We've seen this with AI-powered diagnostics securing IVDR CE marks, with the FDA's focus on predetermined change control plans for adaptive SaMD, and now with cosmetics ingredients that make structure–function claims.

What ties these threads together is the expectation of continuous evidence generation. It's no longer sufficient to demonstrate safety and efficacy at a single point in time. Regulators want to see that you're monitoring outcomes, updating risk assessments, and adapting your product strategy based on post-market data. For AI-enabled platforms, that means building feedback loops into your QMS from day one. For connected devices that recommend formulations, it means tracking user outcomes and correlating them with specific ingredient recommendations. For any product that blurs categories, it means designing your regulatory strategy to accommodate reclassification without starting from scratch.

This is where many teams stumble. They design compliance strategies around static classifications and rigid pathways, then find themselves trapped when regulators redefine the boundaries. The antidote is adaptive regulatory frameworks built on continuous intelligence—systems that track regulatory signals in real time, flag emerging risks before they become enforcement actions, and enable you to pivot strategy without losing momentum.

Key Takeaways

• The FDA's July peptide review will clarify whether structure–function claims trigger device or drug pathways—impacting any beauty-tech product that recommends or validates peptide formulations.
• AI-driven formulation and skin diagnostics are accelerating category convergence, creating dual compliance obligations that traditional cosmetics or device strategies can't address in isolation.
• Teams developing connected devices, diagnostic apps, or personalised skincare platforms need to audit claims, document algorithm decision logic, and build post-market surveillance infrastructure now—before classification shifts force reactive redesigns.
• Regulatory expectations around continuous evidence generation and algorithmic explainability are tightening across cosmetics, devices, and SaMD. Your compliance strategy must be adaptive, not static, to survive boundary redefinitions.
• The peptide review signals broader FDA intent to tighten oversight wherever digital tools and therapeutic claims intersect—making proactive regulatory intelligence essential for any team working at category boundaries.

For regulatory teams navigating these shifting boundaries, the message is clear: convergence creates opportunity, but only for organisations that build compliance strategies capable of flexing across classifications, jurisdictions, and evolving evidence standards. The FDA's peptide review isn't an isolated event—it's a preview of how regulators will manage innovation at the intersection of cosmetics, devices, and digital health for the next decade. Teams that treat it as such, and invest in adaptive infrastructure now, will maintain speed to market when others are forced to rebuild from scratch.